Optain Health Secures $26 Million Series A to Expand AI-Powered Retinal Imaging Platform Globally

Optain Health, a healthcare technology company focused on retinal imaging and AI-driven diagnostics, has successfully closed a $26 million Series A funding round to accelerate its deployment and expansion efforts. The raise was oversubscribed and led by Insight Partners, with participation from existing investors and key health systems across the U.S.

Optain’s platform centers on Oculomics, a non-invasive retinal imaging approach powered by a portable robotic camera and integrated AI algorithms. The system captures retinal images without requiring pupil dilation and applies machine learning workflows to detect eye diseases such as diabetic retinopathy, glaucoma, and age-related macular degeneration, as well as biomarkers associated with systemic conditions like cardiovascular risk.

A distinguishing feature of this round is the involvement not only of traditional venture capital investors but also of strategic health system partners. Among the U.S. health systems joining the investment are Memorial Hermann Health System, Northwell Health, Novant Health, The Ohio State University Wexner Medical Center, and UPMC. Together, these systems serve about 28 million patients across 25 states, and each is expected to begin deploying Optain’s imaging platform across their networks.

Beyond domestic deployment, the funding is expected to underwrite Optain’s expansion into international markets, including Australia, Europe, the Middle East, and Southeast Asia. The company plans to invest in research and development efforts in Australia, leveraging the scientific foundation laid by Professor Mingguang He’s prior work. Optain’s leadership has publicly expressed a commitment to growing its local Australian R&D team to steer global expansion efforts outside the U.S.

At its founding in 2023, Optain secured an initial seed round of around $12 million from backers including Aegis Ventures and Northwell Holdings. According to company data, this latest round brings Optain’s total funding to approximately $38 million.

Optain’s CEO, Jeff Dunkel, commented that after two years of international growth, the company is now poised to scale rapidly in the U.S. The Series A proceeds will support enterprise deployment, entry into new markets, and further development of retina-based diagnostics. In addition, Dr. Zachary Tan, President of Optain, emphasized the company’s intention to translate Australian research into global healthcare impact.

Insight Partners Managing Director Scott Barclay noted that the investment underscores confidence in AI deployed at the clinical edge. He described Optain’s platform as a transformative tool for making retinopathy and other retinal disease screening more accessible, while also serving as a gateway for AI-based diagnostics within primary care workflows.

With strategic backing from both financial investors and health system operators, Optain appears well positioned to roll out its technology across major care networks. The funding milestone marks a critical step in the company’s ambition to embed AI-enabled retinal diagnostics more deeply into standard clinical settings and extend its impact internationally.